|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Guanfacine#Drug Interactions]] |
| {{Guanfacine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be affected significantly by CYP3A4 inhibitors or inducers (Figure 1). Dose adjustments are recommended [see Dosage and Administration (2.7)]. Guanfacine does not significantly affect exposures of methylphenidate and lisdexamfetamine when coadministered (Figure 2). Therefore, no dose adjustments in methylphenidate or lisdexamfetamine are necessary.
| |
| {|
| |
| |[[File:INTUNIV05.jpg|thumb|800px]]
| |
| |}
| |
| | |
| {|
| |
| |[[File:INTUNIV06.jpg|thumb|800px]]
| |
| |}<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INTUNIV (GUANFACINE) TABLET, EXTENDED RELEASE INTUNIV (GUANFACINE) KIT [SHIRE US MANUFACTURING INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b972af81-3a37-40be-9fe1-3ddf59852528#section-12.1 | publisher = | date = | accessdate = 25 February 2014 }}</ref>
| |
| | |
| | |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Antihypertensives and diuretics}}
| |
| {{Antihyperkinetics}}
| |
| {{Adrenergics}}
| |
| | |
| [[Category:Antihypertensive agents]]
| |
| [[Category:Guanidines]]
| |
| [[Category:Alpha-adrenergic agonists]]
| |
| [[Category:Acetamides]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |